# US 11,026,956 B2 · Cancer drug and uses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,026,956 B2 - Document ID: US11026956B2 - Status: Granted - Kind: B2 - Application number: 15/992,537 - Filed: 2018-05-30 - Published: 2018-09-27 - Granted: 2021-06-08 - Earliest claimed: 2013-01-14 - Assignees: Health Clinics Limited - Applicants: Health Clinics Limited - Inventors: Robin M. Bannister; John Brew; Gregory A. Stoloff - Web page: https://patentgrep.com/patent/US11026956B2 ## CPC - A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems - A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21) - A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} - A61K 9/4858: {Organic compounds} - A61K 31/05: Phenols {(cannabinoids A61K31/658)} - A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) - A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) - A61K 31/225: Polycarboxylic acids - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin - A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel - A61K 31/366: having six-membered rings, e.g. delta-lactones - A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof - A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil - A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles - A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine - A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid - A61K 39/39558: {against tumor tissues, cells, antigens} - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual. ## Claims ### Claim 1 A pharmaceutical kit comprising an anti-diabetic drug, a statin, and a glycolysis inhibitor. ### Claim 2 (depends on 1) The pharmaceutical kit according to claim 1, wherein the anti-diabetic drug is a biguanide, a thiazolidinedione, a secretagogue, an alpha-glucosidase inhibitor and/or a peptide analog, a cinnamon, a thiamine, or any combination thereof. ### Claim 3 (depends on 2) The pharmaceutical kit according to claim 2, wherein the biguanide is a metformin, a phenformin, a buformin, or any combination thereof. ### Claim 4 (depends on 1) The pharmaceutical kit according to claim 1, wherein the statin is an atorvastatin, a fluvastin, a lovastatin, a pitavastatin, a pravastatin, a rosuvastatin, a simvastatin, or any combination thereof. ### Claim 5 (depends on 1) The pharmaceutical kit according to claim 1, wherein the glycolysis inhibitor is a hexokinase inhibitor, a phosphoglucose isomerase inhibitor, a fructosebisphosphate inhibitor, a triosephosphate isomerase inhibitor, a glyceraldehyde phosphate dehydrogenase inhibitor, a phosphoglycerate kinase inhibitor, a phosphoglycerate mutase inhibitor, an enolase inhibitor and/or a pyruvate kinase inhibitor, an anti-helminthic agent, an anti-malarial agent, an antibiotic, or any combination thereof. ### Claim 6 (depends on 5) The pharmaceutical kit according to claim 5, comprising an anti-diabetic drug, a statin, an anti-helminthic agent, and an anti-malarial agent. ### Claim 7 (depends on 6) The pharmaceutical kit according to claim 6, wherein the anti-diabetic drug is a biguanide, the anti-helminthic agent is a benzimidazole, and the anti-malarial agent is a doxycycline. ### Claim 8 (depends on 7) The pharmaceutical kit according to claim 7, wherein the biguanide is a metformin, the statin is an atorvastatin, and the benzimidazole is a mebendazole. ### Claim 9 (depends on 5) The pharmaceutical kit according to claim 5, wherein the anti-helminthic agent includes an abamectin, an aminoacetonitriles, a benzimidazole, a diethylcarbamazine, an ivermectin, a levamisole, niclosamide, an octadepsipeptides, a phosphoric acid, a praziquantel, a spiroindoles, a suramin, a pyrantel pamoate, or any combination thereof. ### Claim 10 (depends on 9) The pharmaceutical kit according to claim 9, wherein the benzimidazole is an albendazole, a fenbendazole, a flubendazole, a thiabendazole, a triclabendazole, or any combination thereof. ### Claim 11 (depends on 10) The pharmaceutical kit according to claim 10, wherein the flubendazole is a mebendazole. ### Claim 12 (depends on 5) The pharmaceutical kit according to claim 5, wherein the anti-malarial agent includes an amodiaquine, an artemisinin, an atovaquone, a chloroquine, a clindamycin, a doxycycline, a halofantrine, a mefloquine, a primaquine, a proguanil, a pyrimethamine, a quinine, a rufigallol, a sulphonamide, or any combination thereof. ### Claim 13 (depends on 12) The pharmaceutical kit according to claim 12, wherein the artemisinin is an arteether, an artelinate, an artelinic acid, an artemether, an artemotil, an artemisinin, an artenimol, an arterolane, an artesunate, a dihydroartemisinin, a dihydroartemisinin methyl ether, or any combination thereof. ### Claim 14 (depends on 1) The pharmaceutical kit according to claim 1, further comprising a glucose intake inhibitor. ### Claim 15 (depends on 14) The pharmaceutical kit according to claim 14, wherein the glucose intake inhibitor includes a GLUT-1 receptor inhibitor. ### Claim 16 (depends on 15) The pharmaceutical kit according to claim 15, wherein the GLUT-1 receptor inhibitor is Vitamin C. ### Claim 17 (depends on 1) The pharmaceutical kit according to claim 1, further comprising a lipid intake inhibitor. ### Claim 18 (depends on 17) The pharmaceutical kit according to claim 17, wherein the lipid intake inhibitor includes an LDL receptor inhibitor, an SR-81 inhibitor, an SR-82 inhibitor, a SR-83/CD36 receptor inhibitor, or any combination thereof. ### Claim 19 (depends on 18) The pharmaceutical kit according to claim 18, wherein the LDL receptor inhibitor is Vitamin D. ### Claim 20 The pharmaceutical kit comprising a biguanide, a statin, a benzimidazole, and a cytotoxic antibiotic. ### Claim 21 The pharmaceutical kit comprising a metformin, an atorvastatin, a mebendazole, and a doxycycline.